EU scientists have warned that popular weight-loss drugs like Ozempic and Wegovy, containing semaglutide, are linked to sudden blindness, raising alarms about their safety.
The European Medicines Agency (EMA) announced on Friday, June 6, that a months-long safety review confirmed semaglutide increases the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but severe eye condition. This finding intensifies concerns about the long-term effects of these widely celebrated medications for weight loss and diabetes management.
Naturalnews.com reports: NAION is a condition caused by insufficient blood flow to the optic nerve, the critical structure that transmits visual signals from the eye to the brain. When the nerve is damaged, vision loss can occur suddenly – often without warning. It is the second-leading cause of optic nerve blindness, trailing only glaucoma.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
The EMA’s review found that adults with Type 2 diabetes taking semaglutide face twice the risk of developing NAION compared to those not on the drug. While classified as a “very rare” side effect affecting up to 1 in 10,000 users, the irreversible nature of the condition makes it alarming.
John McAfee Footage Exposes Bill Gates Breeding 'Alien Hybrids' at Epstein's Zorro Ranch
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) launched its investigation in January 2025, scrutinizing clinical trial data, real-world patient reports and medical studies. Given the discovery, thee agency now recommends updating drug labels to reflect this risk – a move that could influence prescribing habits worldwide.
Novo Nordisk responds to EMA’s findings
Novo Nordisk, the Danish pharmaceutical giant behind these drugs, has stated it will comply with the EMA’s request. However, it maintains that the benefits still outweigh the risks.
The company insists that neither clinical trials nor post-market surveillance definitively prove semaglutide causes NAION. However, critics argue that regulators and manufacturers have been slow to address mounting safety concerns, including earlier investigations into suicidal thoughts and kidney cancer risks tied to these medications.
Semaglutide-based drugs have revolutionized obesity and diabetes treatment, generating billions in revenue for Novo Nordisk. But the company has faced turbulence, including the ousting of its CEO in May amid investor fears of losing dominance in the booming weight-loss drug market. Competitors like Eli Lilly’s Zepbound are gaining ground, while patients and doctors now grapple with balancing rapid weight loss against potentially life-altering side effects.
This is not the first time blockbuster drugs have faced scrutiny after widespread adoption. Painkillers like Vioxx and antidepressants such as Paxil were initially celebrated before later being linked to severe cardiovascular risks and suicidal ideation, respectively.
The EMA advises users experiencing sudden vision changes to seek immediate medical attention and consider discontinuing semaglutide if NAION is diagnosed. While the absolute risk remains low, the irreversible damage makes this a critical consideration – especially for those with preexisting eye conditions.
The EMA’s decision could pressure other regulators, including the U.S. Food and Drug Administration (FDA), to revisit semaglutide’s safety profile. The FDA has not announced a similar review as of writing, but past precedents suggest international findings often trigger American action. For millions relying on semaglutide for diabetes or weight management, the EMA’s warning is a sobering reminder: No drug is without risk.
